Chemomab Therapeutics Ltd. (CMMB)
Chemomab Therapeutics Ltd. Statistics
Share Statistics
Chemomab Therapeutics Ltd. has 942.83K shares outstanding. The number of shares has increased by 32.62% in one year.
| Shares Outstanding | 942.83K |
| Shares Change (YoY) | 32.62% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | 828.5K |
| Failed to Deliver (FTD) Shares | 9K |
| FTD / Avg. Volume | 2.43% |
Short Selling Information
The latest short interest is 162.9K, so 0.86% of the outstanding shares have been sold short.
| Short Interest | 162.9K |
| Short % of Shares Out | 0.86% |
| Short % of Float | 0.98% |
| Short Ratio (days to cover) | 1.15 |
Valuation Ratios
The PE ratio is -105.34 and the forward PE ratio is -59.71. Chemomab Therapeutics Ltd.'s PEG ratio is 1.06.
| PE Ratio | -105.34 |
| Forward PE | -59.71 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 0.11 |
| P/FCF Ratio | 0 |
| PEG Ratio | 1.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Chemomab Therapeutics Ltd..
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.98 |
| Quick Ratio | 4.98 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -22.08 |
| Debt / FCF | - |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-697.25 |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 42.5% in the last 52 weeks. The beta is 0.49, so Chemomab Therapeutics Ltd.'s price volatility has been higher than the market average.
| Beta | 0.49 |
| 52-Week Price Change | 42.5% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 36.53 |
| Average Volume (20 Days) | 370.28K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -14.74K |
| Net Income | -13.95K |
| EBITDA | -14.67K |
| EBIT | -14.74K |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 6.07M in cash and 324K in debt, giving a net cash position of 5.75M.
| Cash & Cash Equivalents | 6.07M |
| Total Debt | 324K |
| Net Cash | 5.75M |
| Retained Earnings | -102.62M |
| Total Assets | 16.96M |
| Working Capital | 12.82M |
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0.
| Operating Cash Flow | 0 |
| Capital Expenditures | 0 |
| Free Cash Flow | 0 |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CMMB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CMMB is $9, which is 682.6% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9 |
| Price Target Difference | 682.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Mar 17, 2021. It was a backward split with a ratio of 1:16.
| Last Split Date | Mar 17, 2021 |
| Split Type | backward |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | -10.25 |
| Piotroski F-Score | 3 |